Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression

Journal of Lipid Research

Volumn 54, Issue 9, 2013, Pages 2400-2409

  Parker, Rex A ^a   Garcia, Ricardo ^a   Ryan, Carol S ^a   Liu, Xiaoqin ^a   Shipkova, Petia ^a   Livanov, Valentin ^a   Patel, Pritesh ^a   Ho, Siew P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Bile acid transporter; Cholestasis; CYP7A1; Low desnsity lipoprotein receptor; N ethyl N nitrosourea mutagenesis; Proprotein convertase subtilisin kexin 9 inhibitors; Statins

Indexed keywords

ATORVASTATIN; BILE ACID; CHOLESTEROL; CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; STEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CONTROLLED STUDY; CYP7A1 GENE; CYP8B1 GENE; DRUG EFFECT; EMBRYO; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; HOMEOSTASIS; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER HOMOGENATE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROL METABOLISM; WILD TYPE;

3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS; BILE ACID TRANSPORTER; CHOLESTASIS; CYP7A1; LOW DESNSITY LIPOPROTEIN RECEPTOR; N-ETHYL N-NITROSOUREA MUTAGENESIS; PROPROTEIN CONVERTASE SUBTILISIN-KEXIN-9 INHIBITORS; STATINS;

ANIMALS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DRUG INTERACTIONS; FECES; FEMALE; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; PROPROTEIN CONVERTASES; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES;

EID: 84881259052     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M038331     Document Type: Article

References (26)

1. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, and D. Erlich. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
2. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
3. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
4. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A PCSK9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
5. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
6. Denis, M., J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, C. Lazure, N. G. Seidah, and A. Prat. 2012. Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation. 125: 894-901.
7. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates THE degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102: 2069-2074.
8. Seidah, N. G., and A. Prat. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11: 367-383.
9. Dias, C. S., A. J. Shaywitz, S. M. Wasserman, B. P. Smith, B. Gao, D. S. Stolman, C. P. Crispino, K. V. Smirnakis, M. G. Emery, A. Colbert, et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 60: 1888-1898.
10. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
11. Cordes, S. P. N-ethyl-N-nitrosourea mutagenesis: boarding the mouse mutant express. 2005. Microbiol. Mol. Biol. Rev. 69: 426-439.
12. Gälman, C., A. M. Ostlund-Lindqvist, A. Björquist, S. Schreyer, L. Svensson, B. Angelin, and M. Rudling. 2003. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267.
13. Alnouti, Y., I. Csanaky, and C. Klaassen. 2008. Quantitative profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 873: 209-217.
14. Osono, Y., L. A. Woollett, J. Herz, and J. M. Dietschy. 1995. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J. Clin. Invest. 95: 1124-1132.
15. Russell, D. W. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72: 137-174.
16. Carey, M. C. 1997. Homing-in on the origin of biliary steroids. Gut. 41: 721-722.
17. Uchida, K., H. Takase, Y. Nomura, K. Takeda, N. Takeuchi, and Y. Ishikaw. 1984. Changes in biliary and fecal bile acids in mice after treatments with diosgenin and β-sitosterol. J. Lipid Res. 25: 236-245.
18. Hofmann, A. F., and L. R. Hagey. 2008. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483.
19. Liscum, L., and N. Dahl. 1992. Intracellular cholesterol transport. J. Lipid Res. 33: 1239-1254.
20. Jelinek, D. F., S. Andersson, C. A. Slaughter, and D. W. Russell. 1990. Cloning and regulation of cholesterol 7α -hydroxylase, the rate-limiting enzyme in bile acid synthesis. J. Biol. Chem. 265: 8190-8197.
21. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR -α. Cell. 93: 693-704.
22. Yoshikawa, T., H. Shimano, M. Amemiya-Kudo, N. Yahagi, and A. Hasty. 2001. Identification of LXR-RXR as an activator of the sterol regulatory element binding protein 1c gene promoter. Mol. Cell. Biol. 21: 2991-3000.
23. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.
24. Crestani, M., A. Sadeghpour, D. Stroup, G. Galli, and J. Y. Chiang. 1998. Transcriptional activation of the cholesterol 7 - -hydroxylase gene (CYP7A) by nuclear hormone receptors. J. Lipid Res. 39: 2192-2200.
25. Dawson, P. A., T. Lan, and A. Rao. 2009. Thematic review series, bile acids: bile acid transporters. J. Lipid Res. 50: 2340-2357.
26. Claro da Silva, T., J. E. Polli, and P. W. Swaan. 2013. The solute carrier family 10 (SLC10): Beyond bile acid transport. Mol. Aspects Med. 34: 252-269.